Skip to main content
logo
Bolt Biotherapeutics, Inc. (BOLT)
NASDAQ: BOLT · Real-Time Price · USD
6.33
+0.09 (1.44%)
Nov 3, 2026, 11:59 AM EST - Market open

Bolt Biotherapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
4.77.77.697.885.731.26
Revenue Growth
12.79%0.07%-2.36%37.48%354.68%445.46%
Gross Profit
-16.8-20.84-49.78-53.67-67.39-74.4
Operating Income
-28.48-34.63-68.24-76.2-90.32-92.79
Net Income
-28.74-33.38-63.12-69.2-88.1-98.59
Earnings Per Share
-16.38-17.85-33.06-36.60-47.16-59.40
EPS Growth
------

Cash & Debt
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
17.627.5147.32102.19168.89186.22
Total Debt
21.6222.9625.2120.2222.6124.36
Net Cash (Debt)
-4.034.5522.1181.97146.28161.86
Net Cash Growth
--79.44%-73.02%-43.96%-9.63%1253.27%
Net Cash Per Share
-2.302.4311.5843.3678.3197.52

Cash Flow & CapEx
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-31.45-39.85-61.29-69.53-76.5-57.07
Capital Expenditures
-0.09-0.07-0.04-0.21-1.95-2.34
Free Cash Flow
-31.54-39.92-61.33-69.73-78.46-59.4
Free Cash Flow Growth
------

Margins
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
--270.80%----
Operating Margin
-605.85%-450.07%-887.33%-967.45%-1576.56%-7364.13%
Pretax Margin
-611.47%-433.74%-820.78%-878.58%-1537.76%-7824.68%
Profit Margin
-611.47%-433.74%-820.78%-878.58%-1537.75%-7824.68%
FCF Margin
-670.98%-518.80%-797.53%-885.36%-1369.47%-4714.60%

Valuation
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
-1.362.665.408.55145.00